SCHEMBL25442724

SCHEMBL25442724

CN(C)CCNc1ccc(NCc2ccccc2O)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ PKM P14618 1/20 0.53
▸ MAPT P10636 4/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ HPGD P15428 3/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ GFER P55789 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.43
▸ GPR55 Q9Y2T6 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CA12 O43570 3/20 0.42
▸ CA2 P00918 3/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ CA1 P00915 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25442728 0.85 HPGD (0.50) RAB9ANPC1SMN1; SMN2PKMMAPT
SCHEMBL25167895 0.79 MAPT (0.48) RAB9ANPC1SMN1; SMN2PKMMAPT
SCHEMBL25442725 0.78 MAPT (0.55) RAB9ANPC1SMN1; SMN2PKMMAPT
SCHEMBL25442727 0.76 HPGD (0.49) RAB9ANPC1SMN1; SMN2PKMMAPT
SCHEMBL25167178 0.75 MAPT (0.49) RAB9ANPC1SMN1; SMN2PKMMAPT
SCHEMBL29036800 0.73 CYP2C19 (0.56) CYP2C19TDO2
SCHEMBL25168109 0.73 RAB9A (0.57) RAB9ANPC1SMN1; SMN2PKMMAPT
SCHEMBL5194552 0.72 CA12 (0.69) PKMKDM4ECA12CA2CA9
SCHEMBL11593766 0.71 MAPT (0.81) RAB9ANPC1SMN1; SMN2MAPTHPGD
SCHEMBL25166952 0.71 MAPT (0.44) RAB9ANPC1SMN1; SMN2PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4177246-A1 FUSED OXAZEPINES AS INHIBITORS OF PEROXIREDOXINS Centro Atlántico del Medicamento, SA (ES) 2023-05-10 — — EP disclosed
Send feedback